Predictors of Self-Reported Memory Problems in Patients With Ovarian Cancer Who Have Received Chemotherapy

Jamie S. Myers

Valmi D. Sousa

Heidi S. Donovan

ovarian neoplasms, cognitive impairment
ONF 2010, 37(5), 596-603. DOI: 10.1188/10.ONF.596-603

Purpose/Objectives: To examine the association between self-report of memory problems and the most commonly reported concurrent symptoms by women with ovarian cancer who have received chemotherapy.

Design: Secondary analysis.

Setting: Midwestern university-based school of nursing.

Sample: 638 women with ovarian cancer participating in a larger study who had received chemotherapy and 68 women with ovarian cancer who had not received chemotherapy.

Methods: Responses to a demographic questionnaire, disease and treatment history survey, and symptom severity index were analyzed using Pearson's correlations, hierarchical regression analysis, and Welch t tests for unequal sample size.

Main Research Variables: Self-rating of memory problems, time since chemotherapy, education level, and self-rating of commonly reported symptoms associated with ovarian cancer.

Findings: Nine symptoms accounted for 37% of the variance of memory problems (controlling for time since chemotherapy and education level). Significant predictors of memory problems included fatigue, mood swings, numbness or tingling, and sleep disturbance. Mean scores for self-reported memory problems were significantly different for participants who received chemotherapy compared to those who had not.

Conclusions: Findings suggest that memory problems were common following chemotherapy for ovarian cancer. Additional prospective study is warranted to evaluate potential mechanisms underlying these symptom interactions. Further qualitative study may be of value to describe the patient experience and identify effective coping strategies.

Implications for Nursing: Patient and family education should include information about the potential for memory problems following chemotherapy for ovarian cancer.

Jump to a section


    Ahles, T. A., & Saykin, A. J. (2001). Cognitive effects of standard-dose chemotherapy in patients with cancer. Cancer Investigation, 19, 812-820. doi: 10.1081/CNV-100107743
    Ahles, T. A., & Saykin, A. J. (2007). Candidate mechanisms for chemotherapy-induced cognitive changes. Nature Reviews Cancer, 7, 192-201. doi: 10.1038/nrc2073
    Ahles, T. A., Saykin, A. J., Furstenberg, C. T., Cole, B., Mott, L. A., Skalla, K., … Siberfarb, P. M. (2002). Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. Journal of Clinical Oncology, 20, 485-493.
    American Cancer Society. (2010). Cancer facts and figures, 2010. Atlanta, GA: Author.
    Barnes, D. E., Cauley, J. A., Lui, L. Y., Fink, H. A., McCulloch, C., Stone, K. L., & Yaffe, K. (2007). Women who maintain optimal cognitive function into old age. Journal of the American Geriatric Society, 55, 259-264. doi: 10.1111/j.1532-5415.2007.01040.x
    Beck, S., Dudley, W. N., & Barsevick, A. M. (2005). Pain, sleep disturbance, and fatigue in patients with cancer: Using a mediation model to test a symptom cluster [Online exclusive]. Oncology Nursing Forum, 32, E48-E55. doi: 10.1188/05.ONF.E48-E55
    Bender, C. M., Sereika, S. M., Berga, S. L., Vogel, V. G., Brufsky, A. M., Paraska, K. K., & Ryan, C. M. (2006). Cognitive impairment associated with adjuvant therapy in breast cancer. Psycho-Oncology, 15, 422-430. doi: 10.1002/pon.964
    Bender, C. M., Sereika, S. M., Brufsky, A. M., Ryan, C. M., Vogel, V. G., Rastorgi, P., … Berga, S. L. (2007). Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer. Menopause, 14, 995-998. doi: 10.1097/gme.0b013e318148b28b
    Brezden, C. B., Phillips, K. A., Abdolell, M., Bunston, T., & Tannock, I. F. (2000). Cognitive function in breast cancer patients receiving adjuvant chemotherapy. Journal of Clinical Oncology, 18, 4175-4183.
    Castellon, S. A., Ganz, P. A., Bower, J. E., Peterson, L., Abraham, L., & Greendale, G. A. (2004). Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. Journal of Clinical and Experimental Neuropsychology, 26, 955-969. doi: 10.1080/13803390490510905
    Chen, Y., Jungsuwadee, P., Vore, M., Butterfield, D. A., & St. Clair, D. K. (2007). Collateral damage in cancer chemotherapy: Oxidative stress in nontargeted tissues. Molecular Interventions, 7, 147-155. doi: 10.1124/mi.7.3.6
    Cimprich, B., So, H., Ronis, D. L., & Trask, C. (2005). Pretreatment factors related to cognitive functioning in women newly diagnosed with breast cancer. Psycho-Oncology, 14, 70-78. doi: 10.1002/pon.821
    Cleeland, C. S., Mendoza, T. R., Wang, X. S., Chou, C., Harle, M. T., Morrissey, M., & Engstrom, M. C. (2000). Assessing symptom distress in cancer patients: The M. D. Anderson Symptom Inventory. Cancer, 89, 1634-1646.
    Cohen, J. (1992). A power primer. Psychological Bulletin, 112, 155-159.
    Daffner, K. R., Ryan, K. K., Williams, D. M., Budson, A. E., Rentz, D. M., Wolk, D. A., & Holcomb, P. J. (2006). Increased responsiveness to novelty is associated with successful cognitive aging. Journal of Cognitive Neuroscience, 18, 1759-1773. doi: 10.1162/jocn.2006.18.10.1759
    Donovan, H. S., Ward, S., Sherwood, P., & Serlin, R. (2008). Evaluation of the Symptom Representation Questionnaire (SRQ) for assessing cancer-related symptoms. Journal of Pain and Symptom Management, 35, 242-257. doi: 10.1016/j.jpainsymman.2007.04.017
    Ferguson, R. J., McDonald, B. C., Saykin, A. J., & Ahles, T. A. (2007). Brain structure and function differences in monozygotic twins: Possible effects of breast cancer chemotherapy. Journal of Clinical Oncology, 25, 3866-3870. doi: 10.1200/JCO.2007.10.8639
    Fleishman, S. B. (2004). Treatment of symptom clusters: Pain, depression, and fatigue. Journal of the National Cancer Institute. Monographs, 32, 119-123. doi: 10.1093/jncimonographs/lgh028
    Hart, R. P., Wade, J. B., & Martelli, M. F. (2003). Cognitive impairment in patients with chronic pain: The significance of stress. Current Pain and Headache Reports, 7, 116-126. doi: 10.1007/s11916-003-0021-5
    Hess, L. M., & Insel, K. C. (2007). Chemotherapy-related change in cognitive function: A conceptual model. Oncology Nursing Forum, 24, 981-994. doi: 10.1188/07.ONF.981-994
    Hillman, C. H., Moti, R. W., Pontifex, M. B., Posthuma, D., Stubbe, J. H., Boomsma, D. I., & de Geus, E. J. (2006). Physical activity and cognitive function in a cross-section of younger and older community-dwelling individuals. Health Psychology, 25, 678-687.
    Jacobs, S. R., Jacobsen, P. B., Booth-Jones, M., Wagner, L. I., & Anasetti, C. (2007). Evaluation of the functional assessment of cancer therapy cognitive scale with hematopoietic stem cell transplant patients. Journal of Pain and Symptom Management, 33, 13-23.
    Jenkins, V., Shilling, V., Deutsch, G., Bloomfield, D., Allan, S., Bishop, H., … Winstanley, J. (2006). A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. British Journal of Cancer, 94, 828-834.
    Jenkins, V., Shilling, V., Fallowfield, L., Howell, A., & Hutton, S. (2004). Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psycho-Oncology, 13, 61-66. doi: 10.1002/pon.709
    Klemp, J. R., Stanton, A. L., Kimler, B. F., & Fabian, C. J. (2006). Evaluating the effects of chemotherapy on cognitive function and quality of life in premenopausal women with breast cancer. Paper presented at the San Antonio Breast Cancer Symposium, San Antonio, TX.
    Kreukels, B. P., Schagen, S. B., Ridderinkhof, K. R., Boogerd, W., Hamburger, H. L., Muller, M. J., & van Dam, F. S. (2006). Effects of high-dose and conventional-dose adjuvant chemotherapy on long-term cognitive sequelae in patients with breast cancer: An electrophysiologic study. Clinical Breast Cancer, 7, 67-78. doi: 10.3816/CBC.2006.n.015
    Lee, B., Dantzer, R., Langley, K. E., Bennett, G. J., Dougherty, P. M., Dunn, A. J., … Cleeland, C. S. (2004). A cytokine-based neuroimmunologic mechanism of cancer-related symptoms. Neuroimmunomodulation, 11, 279-282. doi: 10.1159/000079408
    Lenz, E. R., Pugh, L. C., Milligan, R. A., Gift, A. G., & Suppe, F. (1997). The middle-range theory of unpleasant symptoms: An update. Advances in Nursing Science, 19(3), 14-27.
    Lenz, E. R., Suppe, F., Gift, A. G., Pugh, L. C., & Milligan, R. A. (1995). Collaborative development of middle-range nursing theories: Toward a theory of unpleasant symptoms. Advances in Nursing Science, 17(3), 1-13.
    Malmstrom, H., & Karlsson, T. (2003). Cognitive functions in patients with ovarian cancer receiving chemotherapy [Abstract 1855]. Proceedings of the American Society of Clinical Oncologists, 22, 462.
    Myers, J. S. (2009). A comparison of the theory of unpleasant symptoms and the conceptual model of chemotherapy-related changes in cognitive function [Online exclusive]. Oncology Nursing Forum, 12, E1-E10. doi: 10.1188/09.ONF.E1-E10
    O'Shaughnessy, J. (2003). Chemotherapy-related cognitive dysfunction in breast cancer. Seminars in Oncology Nursing, 19(Suppl. 2), 17-24.
    Schagen, S. B., Muller, M. J., Boogerd, W., & van Dam, F. S. (2002). Cognitive dysfunction and chemotherapy: Neuropsychological findings in perspective. Clinical Breast Cancer, 3(Suppl. 3), S100-S1008. doi: 10.3816/CBC.2002.s.020
    Schagen, S. B., van Dam, F. S., Muller, M. J., Boogerd, W., Lindeboom, J., & Bruning, P. F. (1999). Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer, 85, 640-650.
    Shapiro, P. J. (2005). Neurocognitive function (NCF) in long-term survivors of testicular cancer (TC) [Abstract 8034]. Retrieved from
    Tchen, N., Juffs, H. G., Downie, F. P., Yi, Q. L., Hu, H., Chemerynsky, I., & Tannock, I. F. (2003). Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. Journal of Clinical Oncology, 21, 4175-4183.
    Tortolero-Luna, G., & Mitchell, M. F. (2004). The epidemiology of ovarian cancer. Journal of Cellular Biochemistry, 59(S23), 200-207.
    Troy, L., McFarland, K., Littman-Power, S., Kelly, B. J., Walpole, E. T., Wyld, D., & Thomson, D. (2000). Cisplatin-based therapy: A neurological and neuropsychological review. Psycho-Oncology, 9, 29-39.
    van Dam, F. S., Schagen, S. B., Muller, M. J., Boogerd, W., Wall, E., Droogleever Fortuyn, M. E., & Rodenhuis, S. (1998). Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: High-dose versus standard-dose chemotherapy. Journal of the National Cancer Institute, 90, 210-218.
    Wieneke, M. H., & Dienst, E. R. (1995). Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psycho-Oncology, 4, 61-66. doi: 10.1002/pon.2960040108
    Wood, L. J., Nail, L. M., Perrin, N. A., Elsea, C. R., Fischer, A., & Druker, B. J. (2006). The cancer chemotherapy drug etoposide (VP-16) induces proinflammatory cytokine production and sickness behavior-like symptoms in a mouse model of cancer chemotherapy-related symptoms. Biological Research for Nursing, 8, 157-169.
    Yaffe, K., Barnes, D. E., Lindquist, K., Cauley, J. A., Simonsick, E. M., Penninx, B., … Health ABC Investigators. (2007). Endogenous sex hormone levels and risk of cognitive decline in an older biracial cohort. Neurobiology of Aging, 28, 171-178.